Investing News Network on MSN3h
What is In-Licensing?
When it comes to investing in pharmaceutical companies, looking at pipelines and research and development prospects is ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) released additional follow-up results from the Phase ...
With a rumored $8m price tag, the Super Bowl ad stakes are high – but the potential brand rewards are massive. How can ...
The pandemic death total stands at 1,252 as of February 1, 2025 (the most recent data available). The 5 reported deaths last ...
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced additional follow-up ...
Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while ...
Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...
A former NYU housing manager is suing the university for religious-based discrimination, claiming he was wrongfully ...
NIH grant recipients receive additional funding to cover "indirect costs," such as building maintenance and administrative ...